Citations

Clear

6273 citation(s) found for "To, Andrew".

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Streiff, Michael B. , Holmstrom, Bjorn, Angelini, Dana E. , Ashrani, Aneel A. , Diep, Robert , Fogerty, Annemarie E., Gallastegui, Nicolas , Gangaraju, Radhika , Rojas‐Hernandez, Cristhiam M. , Goldhaber, Samuel Z. , Kubal, Timothy, Leavitt, Andrew D., Mann, Janelle , Mantha, Simon , Morton, Colleen , Nester, Alex, O’Brien, Andrew , Ranade, M. , Salmasi, Amirali , Schaefer, Jordan K. , Williams, Eliot C., Wun, Theodore, Nguyen, Jamie , Freedman-Cass, Deborah A., Sliker, Bailee , Ashrani, Aneel, Schaefer, Jordan K , Buckner, Tyler W. , Fertrin, Kleber Yotsumoto , Ibrahim, Ibrahim , Leavitt, Andrew D. , Lim, Ming Y , Mann, Janelle, O’Brien, Andrew, Ortel, Thomas L. , Pine, Alexander B. , Pishko, Allyson M. , Wool, Geoffrey D. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 483-506

10.6004/jnccn.2024.0046 | PMID 39236759 Get It

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.
Multiligament knee injury (MLKI): an expert consensus statement on nomenclature, diagnosis, treatment and rehabilitation
Murray, Iain R. , Makaram, Navnit S. , Moatshe, Gilbert , Crossley, Kay M. , Davis, Aileen M. , Tuca, María , Eun, SeungPyo, Noyes, Frank R. , Marx, Robert G. , Harner, Chris, Levy, Bruce A. , Whelan, Daniel B. , Hatch, George F. Rick , Wahl, Christopher J. , Thorborg, Kristian , Irrgang, James J. , MacDonald, Peter , Shelbourne, K. Donald , Musahl, Volker , Miller, Mark D., LaPrade, Robert F. , Murray, Iain Robert , Moatshe, Gilbert , Crossley, Kay , Davis, Aileen , Janse van Rensburg, Dina C , Emery, Carolyn A , King, Enda , Engebretsen, Lars , Seil, Romain , Verhagen, Evert , Irrgang, James J , LaPrade, Robert F , Geeslin, Andrew G. , Chahla, Jorge , Kew, Michelle Elizabeth , Potter, Hollis G. , Emery, Carolyn A. , Eun, Seung-Pyo, Grindem, Hege , Cook, James L. , Pujol, Nicolas , Medvecky, Michael J. , Stuart, Michael J. , Krych, Aaron J. , Engebretsen, Lars , Stannard, James P. , Seil, Romain , Fanelli, Gregory C. , Maak, Travis G. , Verhagen, Evert , Hirschmann, Michael T. , Schenck, Robert C.

Mayo Clinic

British Journal of Sports Medicine | September 5, 2024 | Volume: 58 | Issue: 23 | Pages: 1385-1400

10.1136/bjsports-2024-108089 | PMID 39237264 Get It

Multiligament knee injuries (MLKIs) represent a broad spectrum of pathology with potentially devastating consequences. Currently, disagreement in the terminology, diagnosis and treatment of these injuries limits clinical care and research. This study aimed to develop consensus on the nomenclature, diagnosis, treatment and rehabilitation strategies for patients with MLKI, while identifying important research priorities for further study. An international consensus process was conducted using validated Delphi methodology in line with British Journal of Sports Medicine guidelines. A multidisciplinary panel of 39 members from 14 countries, completed 3 rounds of online surveys exploring aspects of nomenclature, diagnosis, treatment, rehabilitation and future research priorities. Levels of agreement (LoA) with each statement were rated anonymously on a 5-point Likert scale, with experts encouraged to suggest modifications or additional statements. LoA for consensus in the final round were defined ‘a priori’ if >75% of respondents agreed and fewer than 10% disagreed, and dissenting viewpoints were recorded and discussed. After three Delphi rounds, 50 items (92.6%) reached consensus. Key statements that reached consensus within nomenclature included a clear definition for MLKI (LoA 97.4%) and the need for an updated MLKI classification system that classifies injury mechanism, extent of non-ligamentous structures injured and the presence or absence of dislocation. Within diagnosis, consensus was reached that there should be a low threshold for assessment with CT angiography for MLKI within a high-energy context and for certain injury patterns including bicruciate and PLC injuries (LoA 89.7%). The value of stress radiography or intraoperative fluoroscopy also reached consensus (LoA 89.7%). Within treatment, it was generally agreed that existing literature generally favours operative management of MLKI, particularly for young patients (LoA 100%), and that single-stage surgery should be performed whenever possible (LoA 92.3%). This consensus statement will facilitate clinical communication in MLKI, the care of these patients and future research within MLKI.
Hypofractionated Preoperative Radiation Should Not Yet Be Used as Standard of Care for Extremity and Truncal Soft Tissue Sarcoma
Baldini, Elizabeth H. , Guadagnolo, B. Ashleigh , Salerno, Kilian , Miah, Aisha , Bedi, Meena , Harris, Jeremy P. , Petersen, Ivy A. , Gillham, Charles, Alektiar, Kaled M. , Kirsch, David G. , Petersen, Ivy, Chung, Peter W M , Bishop, Andrew Justin , Kalbasi, Anusha K. , Wiltink, Lisette M. , Haas, Rick L.

Mayo Clinic

Journal of Clinical Oncology | September 4, 2024 | Volume: 42 | Issue: 36 | Pages: 4240-4245

10.1200/jco.24.00238 | PMID 39231372 Get It

Hypofractionated radiation therapy regimens should not be used as standard of care for localized soft tissue sarcoma
Pathological features of connective tissue disease‐associated interstitial lung disease in transbronchial cryobiopsies
Churg, Andrew , Ravaglia, Claudia , Vašáková, Martina , Manjarres, D.C. Gomez, Tazelaar, Henry D. , Wright, Joanne L, Ravaglia, Claudia , Vaszar, Laszlo T. , Tazelaar, Henry, Poletti, Venerino , Matěj, Radoslav , Hornychová, Helena , Stewart, Brian D. , Patel, Divya C. , Duarte, Ernesto Martinez , Mehta, Hiren J. , Tazelaar, Henry D. , Wright, Joanne L

Mayo Clinic

Histopathology | September 3, 2024 | Volume: 86 | Issue: 2 | Pages: 260-267

10.1111/his.15311 | PMID 39223069 Get It

AimTransbronchial cryobiopsies are increasingly used for the diagnosis of interstitial lung disease (ILD), but there is a lack of published information on the features of specific ILD in cryobiopsies. Here we attempt to provide pathological guidelines for separating usual interstitial pneumonia (UIP) of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP) and connective tissue disease‐associated ILD (CTD–ILD) in cryobiopsies.MethodsWe examined 120 cryobiopsies from patients with multidisciplinary discussion (MDD)‐established CTD–ILD and compared them to a prior series of 121 biopsies from patients with MDD‐established IPF or FHP.ResultsA non‐specific interstitial pneumonia (NSIP) pattern alone was seen in 36 of 120 (30%) CTD–ILD, three of 83 (3.6%) FHP and two of 38 (5.2%) IPF cases, statistically favouring a diagnosis of CTD–ILD. The combination of NSIP + OP was present in 29 of 120 (24%) CTD–ILD, two of 83 (2.4%) FHP and none of 38 (0%) IPF cases, favouring a diagnosis of CTD–ILD. A UIP pattern, defined as fibroblast foci plus any of patchy old fibrosis/fibrosis with architectural distortion/honeycombing, was identified in 28 of 120 (23%) CTD–ILD, 45 of 83 (54%) FHP and 27 of 38 (71%) IPF cases and supported a diagnosis of FHP or IPF. The number of lymphoid aggregates/mm2 and fibroblast foci/mm2 was not different in IPF, CTD–ILD or FHP cases with a UIP pattern. Interstitial giant cells supported a diagnosis of FHP or CTD–ILD over IPF, but were infrequent.ConclusionsIn the correct clinical/radiological context the pathological findings of NSIP, and particularly NSIP plus OP, favour a diagnosis of CTD–ILD in a cryobiopsy, but CTD–ILD with a UIP pattern, FHP with a UIP pattern and IPF generally cannot be distinguished.
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial
Desai, Milind Y. , Okushi, Yuichiro , Gaballa, Andrew , Wang, Qiuqing, Geske, Jeffrey B. , Owens, Anjali , Saberi, Sara , Wang, Andrew , Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Naidu, Srihari S. , Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Masri, Ahmad , Zenker, M., Wheeler, M., Bach, R., Rader, F., Bajona, Pietro, Owens, Anjali T , Cremer, Paul C , Sherrid, Mark , Lakdawala, Neal K , Tower-Rader, Albree , Naidu, Srihari S , Sehnert, Amy J , Nissen, Steven E , Popovic, Zoran B , Geske, Jeffrey B , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Fermin, David , Stendahl, John C. , Orford, J.

Mayo Clinic

Circulation: Cardiovascular Imaging | September 2, 2024 | Volume: 17 | Issue: 9 | Pages: No page available

10.1161/circimaging.124.017185 | PMID 39221824 Get It

BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) demonstrated that mavacamten reduces the need for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function. In VALOR-HCM, we assessed serial changes in LV and right ventricular (RV) strain. METHODS: VALOR-HCM included 112 patients with symptomatic obstructive hypertrophic cardiomyopathy (mean, 60 years; 51% male; LV ejection fraction, 68%). Patients assigned to mavacamten at baseline continued the drug for 56 weeks (n=56) and those assigned to placebo (n=52) transitioned to mavacamten from weeks 16 to 56 (40-week exposure). LV-GLS and RV-GLS assessment was performed using a vendor-neutral software. Non-foreshortened apical (4-, 3-, and 2-chamber) views were used to obtain peak LV-GLS. RV focused 4-chamber view was used to calculate RV 4-chamber and free wall strain. A more negative strain value is favorable. RESULTS: At baseline, the mean LV-GLS, RV 4-chamber, and free wall strain values were −14.7%, −22.2%, and −16.8%, respectively (all worse than reported normal means). In the total study sample, LV-GLS significantly improved from baseline to week 56 ( P =0.02). Twelve patients had transient reduction in LV ejection fraction (<50%) requiring temporary drug interruption (including 3 permanent discontinuations). The LV-GLS in this subgroup was worse at baseline versus total study population (−11.4%), with no significant worsening from baseline through week 56 ( P =0.64). Both free wall and 4-chamber RV-GLS remained unchanged from baseline to week 56 ( P =0.62 and P =0.56, respectively). CONCLUSIONS: In VALOR-HCM, treatment with mavacamten improved LV-GLS from baseline through week 56 (with no significant worsening of LV-GLS in patients with a reduction in LV ejection fraction ≤50%), suggesting a favorable long-term impact on regional LV systolic function. Additionally, there was no detrimental impact on RV systolic function. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Bridging the gap: Multi‐omics profiling of brain tissue in Alzheimer's disease and older controls in multi‐ethnic populations
Reddy, Joseph S. , Heath, Laura , Linden, Abby Vander , Allen, Mariet , Lopes, Kátia de Paiva , Wang, Erming , Poehlman, William L. , Quicksall, Zachary , Runnels, Alexi , Duong, Duc M. , Yin, Luming, Xu, Kaiming , Modeste, Erica , Dammer, Eric B. , Ping, Lingyan , Oatman, Stephanie R., Scanlan, Jo, Ho, Charlotte C.G. , Carrasquillo, Minerva M. , Atık, Merve, Yepez, Geovanna, Mitchell, Adriana O., Nguyen, Thuy , Chen, Xianfeng , Reddy, Hasini, Xiao, Harrison, Seshadri, Sudha , Mayeux, Richard , Beach, Thomas G. , Haroutunian, V., Fox, Edward J., Gearing, Marla , Wingo, Aliza P. , Wingo, Thomas S. , Jager, Philip L. De , Zhang, Bin , Bennett, David A. , Seyfried, Nicholas T. , Greenwood, Anna K. , Ertekin‐Taner, Nilüfer , Bennett, David A. , Ho, Charlotte, Greenwood, Anna K , Seshadri, Sudha , Dammer, Eric B , Wingo, Thomas S , Seifar, Fatemeh , Ma, Yiyi , Wang, Yanling , Shantaraman, Anantharaman , Carrasquillo, Minerva M. , Márquez, David X. , Prokop, Stefan , Lee, Edward B. , Serrano, Geidy E. , Teich, Andrew F. , Lah, James J. , Levey, Allan I. , Dickson, Dennis W. , Barnes, Lisa L.

Mayo Clinic

Alzheimer's & Dementia | August 31, 2024 | Volume: 20 | Issue: 10 | Pages: 7174-7192

10.1002/alz.14208 | PMID 39215503 Get It

Abstract INTRODUCTION Multi‐omics studies in Alzheimer's disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are disproportionately affected by AD. METHODS To bridge this gap, Accelerating Medicines Partnership in Alzheimer's Disease (AMP‐AD) expanded brain multi‐omics profiling to multi‐ethnic donors. RESULTS We generated multi‐omics data and curated and harmonized phenotypic data from BA ( n = 306), LA ( n = 326), or BA and LA ( n = 4) brain donors plus non‐Hispanic White ( n = 252) and other ( n = 20) ethnic groups, to establish a foundational dataset enriched for BA and LA participants. This study describes the data available to the research community, including transcriptome from three brain regions, whole genome sequence, and proteome measures. DISCUSSION The inclusion of traditionally underrepresented groups in multi‐omics studies is essential to discovering the full spectrum of precision medicine targets that will be pertinent to all populations affected with AD. Highlights Accelerating Medicines Partnership in Alzheimer's Disease Diversity Initiative led brain tissue profiling in multi‐ethnic populations. Brain multi‐omics data is generated from Black American, Latin American, and non‐Hispanic White donors. RNA, whole genome sequencing and tandem mass tag proteomicsis completed and shared. Multiple brain regions including caudate, temporal and dorsolateral prefrontal cortex were profiled.
Presentation, surgical outcome, and supplementary motor area syndrome risk of posterior superior frontal gyrus tumors
Jusué-Torres, Ignacio , White, Jaclyn J., Bouchal, Samantha M. , Hsu, Andrea R. , Ha, Yooree , Pumford, Andrew D. , Hong, Sukwoo , Riviere-Cazaux, Cécile , Wang, Kimberly , Helal, Ahmed , Brown, Desmond A., Jusue-Torres, Ignacio , Bouchal, Samantha M , Bauman, Megan M. J. , Brown, Desmond , Parney, Ian F.

Mayo Clinic

Journal of Neurosurgery | August 31, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.3171/2024.5.jns231850 | PMID 39213666 Get It

OBJECTIVE Following resection of posterior superior frontal gyrus (PSFG) tumors, patients can experience supplementary motor area (SMA) syndrome consisting of contralateral hemiapraxia and/or speech apraxia. Given the heterogeneity of PSFG tumors, the authors sought to determine the risk of postoperative deficits and assess predictors of outcomes for all intraparenchymal PSFG tumors undergoing surgery (biopsy or resection), regardless of histology. METHODS This was a retrospective single-center cohort study of adult PSFG-region tumors undergoing biopsy or resection by a single surgeon. RESULTS A total of 106 consecutive patients undergoing 123 procedures (21 biopsies, 102 resections) fulfilled inclusion and exclusion criteria. Anaplastic astrocytomas were the most frequent among resected tumors (39% vs 29%), while glioblastomas were most common among biopsies (38% vs 27%) (p < 0.0001). The biopsy cohort was more likely to have tumor involvement outside the PSFG (90% vs 62%) (p = 0.011), most commonly in the motor cortex (67% vs 31%) (p = 0.005). Seizures were the most common presenting symptom in the resection cohort (p = 0.017), while motor deficits were more common in the biopsy cohort (58% vs 29%) (p < 0.001). Immediate postoperative neurological deficits occurred in 71 cases (58%), but only 3 of the deficits were permanent at 6 months of follow-up (2%). Postoperative SMA syndrome occurred in 48 cases (47%) and was significantly associated with involvement of the motor cortex (p = 0.018) or cingulate gyrus (p = 0.023), which were also significant in multivariate analysis as risk factors for SMA syndrome. However, postoperative SMA syndrome was not significantly associated with overall survival (p = 0.51). There were no perioperative deaths, but corpus callosum involvement (p < 0.001), contrast enhancement (p = 0.003), and glioblastoma pathology (p = 0.038) predicted worse overall survival in patients undergoing resection. CONCLUSIONS Nearly half of all patients undergoing resection of PSFG-region tumors experience a postoperative SMA syndrome. Individuals with corpus callosum and/or motor cortex involvement may be at an increased risk of experiencing SMA syndrome. However, these deficits are usually transient, and the risk of permanent new deficits is very low (3%). Preoperative characteristics including corpus callosum involvement and tumor enhancement—in addition to pathology—might serve as predictors of overall survival within this patient population.
Life‐threatening hemorrhage as defined by the critical administration threshold in nontraumatic critical bleeding: A descriptive observational study
Matzek, Luke J. , Hanson, Andrew C. , Schulte, Phillip J. , Cureton, Kimberly D., Kor, Daryl J. , Warner, Matthew A. , Warner, Matthew A

Mayo Clinic

Transfusion | August 30, 2024 | Volume: 64 | Issue: 10 | Pages: 1841-1850

10.1111/trf.17996 | PMID 39210684 Get It

AbstractBackgroundEvaluations of critical bleeding and massive transfusion have focused on traumatic hemorrhage. However, most critical bleeding in hospitalized patients occurs outside trauma. The purpose of this study was to provide an in‐depth description examining the critical administration threshold (CAT; ≥3 units red blood cells (RBCs) in a 1‐h period) occurrences in nontraumatic hemorrhage. This will assist in establishing the framework for future investigations in nontraumatic hemorrhage.MethodsThis is an observational cohort study of adults experiencing critical bleeding defined as being CAT+ during hospitalization from 2016 to 2021 at a single academic institution. A CAT episode started with administration of the first qualifying RBC unit and ended at the time of completion of the last allogeneic unit prior to a ≥4‐h gap without subsequent transfusion. The primary goal was to describe demographic, clinical and transfusion characteristics of participants with nontraumatic critical bleeding.Results2433 patients suffered critical bleeding, most often occurring in the operating room (71.1%) followed by the intensive care unit (20.8%). 57% occurred on the initial day of hospitalization, with a median duration of 138 (36, 303) minutes. The median number of RBCs transfused during the episode was 5 (4, 8), with median total allogeneic units of 9 (4, 9). Hospital mortality was 19.2%. The most common cause of death was multi‐organ failure (50.3%), however death within 24 h was due to exsanguination (72.7%).DiscussionThe critical administration threshold may be employed to identify critical bleeding in non‐trauma settings of life‐threatening hemorrhage, with a mortality rate of approximately 20%.